Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated February 25, 2026
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India Limited reported strong Q4 FY25 results with revenue of ₹2,510 million, up 47% year-on-year, driven by 23% growth in domestic sales (supported by the relaunch of recalled products) and a 9.3x surge in export sales from a low base. Profit after tax for the quarter rose 50% to ₹665 million. For the full year ending December 2025, revenue grew 21% to ₹8,784 million and net profit climbed 33% to ₹2,401 million, helped by disciplined cost management and improved product mix. Export sales for the year jumped 158% on a low base. The Board declared a dividend of ₹75 per share for FY25. The company operates independently since its demerger from Sanofi India Limited on 1st June 2024, with key brands including Allegra, DePURA, Avil, and Combiflam.
Strong double-digit growth across revenue, profits, and a healthy ₹75 per share dividend signal robust operational performance and should be viewed positively by shareholders. The post-demerger trajectory shows the company is delivering on its growth agenda with both domestic and export momentum.